MEDIFILE: Strontium Ranelate: The First Dual Action Bone Agent
Abstract
This edition of Medifile reviews a new drug, strontium ranelate. Protos® (strontium ranelate) is the first dual action bone agent registered for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and peripheral fractures, including the hip.
Issue
Section
Regulars
By submitting manuscripts to SAFP, authors of original articles are assigning copyright to the South African Academy of Family Physicians. Copyright of review articles are assigned to the Publisher, Medpharm Publications (Pty) Ltd, unless otherwise specified. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAFP for educational and research purposes without obtaining permission.
